FDA Approves Busulfex Injection
WASHINGTON-The FDA has approved Orphan Medical’s Busulfex (busulfan) Injection for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). (See Oncology News International, February 1999, for a report on the Oncology Drugs Advisory Committee’s discussion of the agent and its recommendation to the FDA.)
WASHINGTONThe FDA has approved Orphan Medicals Busulfex (busulfan) Injection for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). (See Oncology News International, February 1999, for a report on the Oncology Drugs Advisory Committees discussion of the agent and its recommendation to the FDA.)
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
